Objectives: On August 14, 2014, the US Food & Drug Administration approved bevacizumab for advanced cervical cancer based on Gynecologic Oncology Group (GOG) protocol 240, the randomized phase 3 clinical trial which demonstrated significantly improved overall survival with chemotherapy plus bevacizumab compared to chemotherapy alone. Although the signal for efficacy of bevacizumab was not observed in a subgroup analysis of prognostic factors for ACs, this histologic type comprised only 20% of the GOG 240 population. We sought to determine whether VEGF pathway
biomarkers were differentially expressed between SCCA and AC of the cervix.